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Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling 
(Mac-2結合蛋白糖鎖修飾異性体はmTORシグナル伝達経路を活性化することにより肝細胞癌の悪性度を増悪させる） 
Background: Liver cancer is the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the most common type of 
primary liver cancer, mostly occurs in people with liver cirrhosis. For HCC patients with severe liver fibrosis, treatment option is limited. Therefore, 
deeper understanding of HCC in fibrotic liver is important for clinical management of HCC. Wisteria floribunda agglutinin (WFA)+ Mac-2 binding 
protein (M2BPGi) is a novel serum marker for liver fibrosis. Clinical studies reported that an elevated serum level of M2BPGi can predict development 
of HCC in cirrhotic liver and poor prognosis of HCC patients after hepatic resection. By experimental study, M2BPGi is produced by hepatic stellate 
cell in the patients with liver fibrosis. However, no studies explained relationship between M2BPGi and aggressiveness of HCC. Galectin-3 in the most 
known binding partner of M2BP, and high expression of galectin-3 in HCC is associated with poor prognosis. Therefore, this study aimed to clarify the 
localization of M2BPGi, galectin-3 and M2BP mRNA on the HCC tissue, further to analyze effect of M2BPGi against HCC.   
Materials and method: The protein expression of M2BPGi and galectin-3 and the mRNA expression of M2BP were evaluated in surgically resected 
human HCC samples. Localization of proteins were evaluated using immunofluorescence method, while M2BP mRNA were detected using 
RNAscope assay. Recombinant M2BPGi (rM2BPGi) were used to analyze the function on the human HCC cell lines (PLC/PRF/5, HepG2 and Huh7) 
using proliferation, invasion and wound healing assay. In addition, effect of M2BPGi on HCC were evaluated in-vivo on the subcutaneous xenograft 
using subcutaneous mini-osmotic pump for constant administration of treatment. To check importance of M2BP ligand, we downregulated galectin-3 
in the HCC cells by siRNA transfection, further the cells are treated with rM2BPGi and underwent functional assessment. Galectin-3 and M2BP 
binding were evaluated HCC cell lysate with and without rM2BPGi using co-immunoprecipitation method. Transcriptome analysis were performed on 
HCC cell lines with and without rM2BPGi treatment. Rapamycin (mTOR inhibitor) used to confirm the result of transcriptome analysis.   
Results: By immunofluorescence study, M2BPGi and galectin-3, as a ligand of M2BP, were co-localized on the HCC cells in the tumor area of the 
tissue. In the adjacent non-tumor area, M2BPGi and galectin-3 were co-localized on the CD68 positive cells (Kupffer cell). M2BP mRNA were 
expressed on stroma of the cirrhotic liver and HCC. rM2BPGi enhanced the proliferation and invasion of the HCC cells. In-vivo experiment confirmed 
that treatment of M2BPGi promoted tumor growth in HCC-bearing mouse model. In addition, the ki-67 labeling index was higher in M2BPGi-treated 
tumors than in PBS-treated tumors. Proliferation invasion ability of M2BPGi treated HCC cell were decreased due to galectin-3 downregulation. Co-
immunoprecipitation analysis showed cellular galectin-3 binds with rM2BPGi on the HCC cell line. In addition, rM2BPGi treatment enhanced the 
membranous galectin-3 expression on the HCC cell. Transcriptome analysis revealed that activation of mTOR signaling due to M2BPGi treatment on 
HCC cell line. Activation of mTOR signaling in the HCC cell were analyzed after M2BPGi treatment by western blotting. Proliferation of M2BPGi-
treated cells were decreased after treatment of mTOR inhibitor. Moreover, M2BPGi-induced mTOR signaling were cancelled by galectin-3 
downregulation in the HCC cell line.   
Discussion: In this study, we focused on the liver fibrosis marker, M2BPGi and its binding partner galectin-3 in the HCC. Our result suggested that 
M2BPGi is derived from stromal cells of the cirrhotic liver and may be interact with HCC cells by galectin-3. We further showed that M2BPGi could 
bind to and induce the membrane expression of galectin-3 on the HCC cells. Moreover, M2BPGi promoted HCC malignancy in vitro by binding with 
galectin-3, which consequently activated mTOR signaling. This was confirmed by the observation that galectin-3 knockdown significantly inhibited 
the effect of M2BPGi on HCC cells. Our in vivo findings were consistent with the in vitro data and further demonstrated the importance of M2BPGi-
induced mTOR signaling on HCC growth.  Other researchers has reported that activation of mTOR signaling is potential indicator of poor prognosis 
in patients with HCC however mTOR inhibitor treatment did not improve the clinical efficacy in patients with advanced HCC. Therefore our findings 
suggests that mTOR inhibitor treatment might be helpful for the treatment of mTOR-activated HCC patients with high level of M2BPGi.  
  
Conclusion: M2BPGi is produced by stromal cells in the cirrhotic liver and interact with HCC cells, further it enhances the progression of HCC by 
activating mTOR signaling in the presence of galectin-3. M2BPGi may serve as a link between HCC and stromal cells and may thus explain the 
fundamental mechanism underlying HCC progression. Accordingly, M2BPGi may be a promising therapeutic target in patients with liver cirrhosis 
who develop HCC. (Word count: 765)                                                                                
